Extended Data Fig. 8: Gating strategies and treatment schemes.
From: Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression
a, Hematopoesis schema. HSC: hematopoietic stem cell, MPP: multipotent progenitor, CLP: common lymphoid progenitor, CMP: common myeloid progenitor, GMP: granulocyte-monocyte progenitor, MDP: monocyte-dendritic cell progenitor, CDP: common dendritic progenitor, DC: dendritic cell. b, Flow cytometry gating strategy of cells isolated from bone marrow. The schema represents the sequential steps of the gating strategy. The various cell populations within the bone marrow are depicted. LSK (Linneg, Sca1pos, CD127neg, c-kitpos) and LK (Linneg, Sca1neg, CD127neg, c-kitpos) hematopoietic precursors and CMP (Linneg, Sca1neg, CD127neg, c-kitpos, CD16/CD32neg) and GMP (Linneg, Sca1neg, CD127neg, c-kitpos, CD16/CD32pos) myeloid precursors. c, Schematic of the TMZ treatment strategy. d, Flow cytometry gating strategy of cells isolated from normal brain. The schema represents the sequential steps of the gating strategy. The various immune cell populations within the brain are depicted. e, Flow cytometry data for the indicated cell types from brain, bone marrow and spleen tissues of control and TMZ (25 mg/kg or 66.7 mg/kg daily) treated mice. Data represent mean ± SEM of biologically independent replicates. n = 4, 4, and 4 for control, 25 and 66.7 mg/kg of TMZ respectively for brain microglia, brain macrophages and spleen myeloid 24, 72 and 168 hrs. n = 5, 2 and 3 for control, 25 and 66.7 mg/kg of TMZ respectively for bone marrow CMP. n = 4, 3 and 2 for control, 25 and 66.7 mg/kg of TMZ respectively for bone marrow GMP. *p = 0.0228, **p = 0.0002, ***p < 0.0001, unpaired t test two-tailed. f, Schematic of the TMZ treatment strategy. g, Longitudinal BLI from representative GBM mice undergoing TMZ treatments. h, Flow cytometry from spleens of GBM mice treated with control vehicle, 25 and 66.7 mg/kg of TMZ. Data is presented as mean ± SD of biologically independent replicates n = 4, 3 and 5 for control, 25 and 66.7 mg/kg TMZ respectively, no statistically significant differences were identified. i, Schematic of the TMZ/IR treatment strategy. j, Longitudinal BLI from representative GBM mice undergoing TMZ and/or IR treatments.
